We studied 112 patients (77 sickle cell anemia, 22 β-thalassemia intermedia and 13 HbE-β-thalassemia) who were on hydroxyurea therapy for 2 years for their response towards hyperbilirubinemia associated with UGT1A1 promoter polymorphism.<h4 class=""h4"">Resultsh3>
The patients with (TA)7/(TA)7 repeats had significantly higher serum bilirubin levels than those with (TA)6/(TA)6 repeats in all the groups and the reduction in serum bilirubin after hydroxyurea therapy was still higher among patients with (TA)7/(TA)7 repeats when compared with (TA)6/(TA)6 repeats.<h4 class=""h4"">Conclusionsh3>
Higher bilirubin levels were associated with the (TA)7/(TA)7 sequence however they did not come down to normal levels after hydroxyurea therapy.